Safety and Risk Assessment of No-Prescription Online Semaglutide Purchases.
作者信息
Ashraf Amir Reza, Mackey Tim K, Schmidt János, Kulcsár Gyozo, Vida Róbert György, Li Jiawei, Fittler András
机构信息
Department of Pharmaceutics, Faculty of Pharmacy, University of Pécs, Pécs, Hungary.
Global Health Program, Department of Anthropology, University of California San Diego, La Jolla.
出版信息
JAMA Netw Open. 2024 Aug 1;7(8):e2428280. doi: 10.1001/jamanetworkopen.2024.28280.
Abstract
摘要
相似文献
1
Safety and Risk Assessment of No-Prescription Online Semaglutide Purchases.
JAMA Netw Open. 2024 Aug 1;7(8):e2428280. doi: 10.1001/jamanetworkopen.2024.28280.
2
Oral semaglutide (Rybelsus) for type 2 diabetes.
Med Lett Drugs Ther. 2019 Oct 21;61(1583):166-168.
3
Semaglutide and Opioid Overdose Risk in Patients With Type 2 Diabetes and Opioid Use Disorder.
JAMA Netw Open. 2024 Sep 3;7(9):e2435247. doi: 10.1001/jamanetworkopen.2024.35247.
4
A new indication for semaglutide (Wegovy).
Med Lett Drugs Ther. 2024 Apr 29;66(1701):66-67. doi: 10.58347/tml.2024.1701b.
5
No association between semaglutide and postoperative pneumonia in people with diabetes undergoing elective surgery.
Diabetes Obes Metab. 2024 Sep;26(9):4105-4110. doi: 10.1111/dom.15711. Epub 2024 Jun 11.
6
Semaglutide and weight loss - A concern for diabetics and pharmaceuticals.
J Pak Med Assoc. 2024 Jun;74(6):1204. doi: 10.47391/JPMA.10705.
7
Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.
Lancet Diabetes Endocrinol. 2019 Nov;7(11):834-844. doi: 10.1016/S2213-8587(19)30311-0. Epub 2019 Sep 17.
8
Diabetic kidney disease: The fourth pharmacological pillar may be semaglutide.
Diabetes Obes Metab. 2024 Nov;26(11):4813-4815. doi: 10.1111/dom.15892. Epub 2024 Sep 2.
9
Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.
N Engl J Med. 2024 Jul 25;391(4):380-381. doi: 10.1056/NEJMc2406233.
10
Study: Semaglutide Lowered Chronic Kidney Disease-Related Risks.
JAMA. 2024 Jul 16;332(3):188. doi: 10.1001/jama.2024.10349.
引用本文的文献
1
Bariatric and metabolic surgery medical tourism: the compelling need for regulation through transnational collaboration.
BMJ Glob Health. 2025 Jul 15;10(7):e019546. doi: 10.1136/bmjgh-2025-019546.
2
Global Rise of Compounded Weight-Loss Medicines: A Worrisome Trend.
J Endocr Soc. 2025 Jun 7;9(8):bvaf084. doi: 10.1210/jendso/bvaf084. eCollection 2025 Aug.
3
A comparison of Glucagon-like peptide-1 receptor agonists on weight change, side effects, and quality of life in Kuwait.
Front Nutr. 2025 May 19;12:1590379. doi: 10.3389/fnut.2025.1590379. eCollection 2025.
4
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025.
Diabetes Care. 2025 Jan 1;48(Supplement_1):S181-S206. doi: 10.2337/dc25-S009.
5
Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study.
J Med Internet Res. 2024 Nov 7;26:e65440. doi: 10.2196/65440.
6
Editorial: Internet pharmacies and the online pharmacy market: trends, perspectives and challenges.
Front Pharmacol. 2024 Sep 25;15:1489396. doi: 10.3389/fphar.2024.1489396. eCollection 2024.
本文引用的文献
1
As Ozempic's Popularity Soars, Here's What to Know About Semaglutide and Weight Loss.
JAMA. 2023 May 16;329(19):1627-1629. doi: 10.1001/jama.2023.2438.
2
Multifactor Quality and Safety Analysis of Antimicrobial Drugs Sold by Online Pharmacies That Do Not Require a Prescription: Multiphase Observational, Content Analysis, and Product Evaluation Study.
JMIR Public Health Surveill. 2022 Dec 23;8(12):e41834. doi: 10.2196/41834.
3
A simplified checklist for the visual inspection of finished pharmaceutical products: a way to empower frontline health workers in the fight against poor-quality medicines.
J Pharm Policy Pract. 2020 May 1;13:9. doi: 10.1186/s40545-020-00211-9. eCollection 2020.
Zotero 插件